Bioavailable Turmeric Supplement Tested Against Cognitive Decline in Metabolic Syndrome
The EPICURO trial tests MERIVA® turmeric over 6 months to see if it protects cognition in adults with metabolic syndrome.
Summary
The EPICURO study is a completed clinical trial investigating whether six months of supplementation with MERIVA®, a highly bioavailable form of curcumin derived from turmeric, can improve cognitive performance and reduce inflammation in adults with metabolic syndrome. Metabolic syndrome — a cluster of conditions including high blood sugar, excess abdominal fat, and elevated blood pressure — is increasingly recognized as a risk factor for cognitive decline and Alzheimer's disease. The trial enrolled 85 participants and used a placebo-controlled design to measure changes in inflammatory, oxidative, and metabolic markers alongside cognitive outcomes. Results from this industry-sponsored trial could help clarify whether enhanced curcumin bioavailability translates into meaningful brain-health benefits for a high-risk population.
Detailed Summary
Metabolic syndrome affects roughly one in three adults in Western countries and is now understood to significantly elevate the risk of age-related cognitive decline and Alzheimer's disease. Chronic low-grade inflammation and oxidative stress — hallmarks of metabolic syndrome — are thought to accelerate neurodegeneration, making this population an important target for preventive interventions.
The EPICURO trial set out to test whether MERIVA®, a phospholipid-complexed form of curcumin designed for superior gastrointestinal absorption, could meaningfully improve cognitive performance and reduce the biological drivers of cognitive decline. Standard curcumin from turmeric has notoriously poor bioavailability, so MERIVA®'s enhanced absorption profile makes it a more pharmacologically relevant candidate for clinical testing.
The randomized, placebo-controlled trial enrolled 85 male and female participants diagnosed with metabolic syndrome and mild cognitive impairment. Over six months, participants received either MERIVA® tablets or placebo. Outcomes included cognitive performance assessments alongside inflammatory, oxidative stress, and metabolic biomarkers. The trial was sponsored by Indena S.p.A., the manufacturer of MERIVA®.
While the trial is listed as completed, full results have not yet been published in the peer-reviewed literature. If positive, findings would support curcumin supplementation as a low-risk, accessible strategy for preserving cognition in a metabolically vulnerable population — a group for whom few preventive pharmacological options currently exist.
Several caveats apply. The relatively small sample size of 85 limits statistical power. Industry sponsorship by the ingredient manufacturer introduces potential bias. The six-month duration may be insufficient to detect meaningful cognitive change. Additionally, this summary is based solely on the trial registration abstract, and published outcome data are not yet available for evaluation.
Key Findings
- MERIVA® curcumin was tested over 6 months in 85 adults with metabolic syndrome and mild cognitive impairment.
- Trial measured both cognitive performance and inflammatory, oxidative, and metabolic biomarkers simultaneously.
- Enhanced bioavailability formulation addresses the key limitation of standard curcumin supplements.
- Metabolic syndrome is an established risk factor for Alzheimer's — making this population a high-value prevention target.
- Full results are pending publication; no outcome data are available from the abstract alone.
Methodology
Randomized, placebo-controlled trial enrolling 85 participants with metabolic syndrome and mild cognitive impairment. Intervention was 6 months of MERIVA® (phospholipid-complexed curcumin) versus placebo tablets. Outcomes spanned cognitive assessments and inflammatory, oxidative, and metabolic biomarkers.
Study Limitations
This summary is based on the trial registration abstract only, as no peer-reviewed results have been published. The small sample size of 85 participants limits statistical power, and industry sponsorship by the ingredient manufacturer introduces potential bias. A six-month intervention window may be too short to detect clinically meaningful cognitive changes.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.